Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в листопаді 2018 (uk)
- im August 2018 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu n'agostu de 2018 (ast)
- scientific article published on 11 August 2018 (en)
- 2018 թվականի օգոստոսի 11-ին հրատարակված գիտական հոդված (hy)
|
publication date
| |
publication date
| |
language of work or name
| |
language of work or name
| |
exact match
| |
exact match
| |
cites work
| |
cites work
| |
author name string
| |
author name string
| - Emilio Bouza
- Maria J G T Vehreschild
- Florian Thalhammer
- Areti Georgopali
- Graham Wetherill
- Joop van Oene
- Surabhi Taori
|
rdfs:label
| - Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
- Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (nl)
|
skos:prefLabel
| - Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
- Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (nl)
|
name
| - Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
- Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (nl)
|
author
| |
author
| |
title
| |
title
| - Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
issue
| |
volume
| |
issue
| |
volume
| |